Auburn University

Altimmune, Inc.

Metin Colpan

Henry J Baker

Tatiana I Samoylova

Nancy R Cox

Ludmila Globa

Kent R Van Kampen

Bruce F Smith

Nancy E Morrison

Stephen Ditchkoff

Valery A Petrenko

Joachim Schorr

Tatiana I Samoilova

Allan E David

M Scot Roberts

Aime K Johnson

Prachi Sangle

Brenda Griffin

Kristina Pendergrass

M Daniel Givens

Kay P Riddell

Therapeutic or prophylactic compositions providing an active agent, such as an antigen or a vector that contains and expresses an antigen, encapsulated in or incorporated into a biodegradable polymeric particle are provided. The compositions can also provide an active agent that is not encapsulated in or incorporated into the biodegradable polymeric particle in order to provide an initial or prime delivery of the active agent. Particles or composites providing an active agent encapsulated by a first and second polymer are also provided, wherein polymers are distributed in a gradient from a core of the composite to a surface of the composite, and configured to provide a delayed release of the active agent by a period of 7 days to 6 months. Methods of producing composites are also provided. Pharmaceutical formulations providing a single dose composition are also provided, along with methods for administering the pharmaceutical compositions to a subject in need thereof a therapeutically effective amount of an active agent are provided.

Biodegradable polymeric particles encapsulating an active agent, pharmaceutical compositions and uses thereof

Disclosed are methods, compositions, zona pellucida binding peptides and polypeptides, and expression vectors for use in species-specific immunocontraception of animals. The disclosed compositions may include immunogenic compositions or vaccines.

Zona pellucida binding peptides for species specific immunocontraception of animals

Disclosed are methods of identifying peptides and compositions that bind to oocytes of animals in a species-specific manner. The methods utilize phage libraries and oocytes isolated from target species and non-target species.

Methods of identifying peptides and compositions that bind to oocytes in a species-specific manner

Disclosed are methods, compositions, and zona pellucida binding peptides and polypeptides for use in immunocontraception of canines and other animals. The disclosed compositions may include pharmaceutical compositions. Methods for identifying peptides that bind to intact oocytes also are provided, in particular methods for identifying peptides that bind to zona pellucida of intact oocytes.

Methods for identifying peptides that bind to intact oocytes

A diagnostic technique for matching anti-cancer peptide drugs to the molecular profiles of individual cancer tumors, and a method using the technique for a patient-specific treatment of tumors in mammals. This strategy matches anti-cancer peptide drugs to the molecular profiles of individual tumors, and includes the development of two banks, both of which use the same targeting peptides. Targeting peptides are identified using biopsies or other tissue materials from multiple cancer patients and placed into two banks. For a bank of probes, targeting peptides are linked to a label such as a fluorescent or a radioisotope. For a bank of drugs, targeting peptides are linked to a cytotoxic peptide to form a 'targeting peptide drug'. Peptide probes are used to establish molecular profiles of individual tumors. Based on these molecular profiles, a patient-specific combination of targeting drugs from the bank of peptide drugs is prepared and the patient is treated. Any currently used cytotoxic agent that can be linked to targeting peptides may be used in place of cytotoxic peptides.

Methods for targeting and killing glioma cells

Compositions for use in characterization, diagnosis, prognosis, and therapy of cancer cells are provided. The compositions comprise peptides and variants thereof which were isolated based on their ability to selectively bind glioma cells.

Peptides for recognition and targeting of GLIAL cell tumors

The general field of the invention is a method for nucleic acid vaccination for animals to protect them from parvoviral infection. This invention is more particularly related to the preparation and use of parvoviral DNA and its administration to dogs, cats and mink so as to induce an immune response that can protect these animals from disease caused by virulante parvovirus. Nucleic acid immunogens are designed to include the antigenic portions of the parvoviral genome which are incorporated into bacterial plasmids. These plasmids produce the desired parvoviral gene product when introduced into host cells by transfection. Host cells transfected with the parvoviral immunogen expressing plasmids produce a stream ot antigenic proteins to which the host immune system will mount a protective immune response.

Nucleic acid vaccination for parvoviral infections

Compositions for use in targeting therapies to central nervous system (CNS) cells are provided. The compositions comprise peptides which are capable of binding CNS cells in vivo.

Growing community of inventors

Auburn, AL, United States of America

Henry J Baker